OncoSil Medical Ltd
OncoSil Medical Ltd (ASX: OSL) is a medical product company, which is working on improving the radiation procedure for cancer patients. The Companyâs lead product, OncoSilâ¢ is set directly into a patientâs affected pancreatic tumours via an ultrasound (endoscopic). OncoSil has held 4 clinical studies with positive results on efficacy, safety and tolerability.
To commercially sell the application in Europe, a CE Mark application approval is necessary. OSL had recently notified the market that, it had obtained guidance from the BSI Clinical Oversight Committee, which was doing the review work on the OncoSilâ¢ CE Mark file.
Further, the company mentioned that, the Clinical Oversight Committee was of the view that insufficient clinical benefit had been demonstrated and hence it declined to provide approval for the application. The company has been in discussion with BSI post the notification of the committeeâs assessment. The CE marking as of 29 March 2019 was put on hold pending a meeting between the company, the Clinical Oversight Committee and BSI.
The company has reported results for half-yearly ended 31 December 2018. Revenues from ordinary activities were up by 6.3% to $1.9 million on pcp basis. The Loss for the half-year was up by 13.6% to $5.15 million. The company received $4.3 million as a cash refund under the R&D Tax Incentive Refund scheme in September 2018. On the operational front, the company completed several major milestones and made early commercialisation strategy and clinical progress in the US.
- US FDA had provided approval for the company to proceed to a full US pivotal study without further US patient data.
- The rate of resection for the PanCO study stood at 24%.
- Eight out of ten tests had reported positive outcomes which was a solid indicator of better survival.
On the stock price performance front, OSL has witnessed a drop in its stock price. In the past year, the share has delivered a negative 60.00% returns. In the recent past, the share price has been in a downward trajectory, and it has delivered a negative return of 69.14%, 68.24%, and 67.27% in the past six months, three months, and one-month respectively. The stock of the company last traded at A$0.054 as on 18 April 2019. The stock has demonstrated negative YTD return of 69.14%.
Patrys Limited (ASX: PAB) is a company domiciled in Melbourne, concentrating on the development of antibodies for the treatment of cancer. It has anti-cancer antibodies in the pipeline for both as partnering opportunities and internal development.
The company has been pursuing a range of activities, and an update on the same was provided by it.
PAT-DX1 process development- The company had roped in a global facility enabler for the development of PAT-DX1. This step marked as a progression of PAT-DX1 towards the clinic.
On the Pre-clinical development of PAT-DX1, the company reported the data from PAT-DX1 plus radiation in a mouse of triple model of triple negative breast cancer brain metastases, and PAT-DX1 plus radiation in a mouse model of glioblastoma, at the stage of this update provided by the company, it believed that it will be able to report on its third study before the end of H1, 2019.
The company had received first patent granted for Deoxymab 5C6, the patent is titled âCell Penetrating Nucleolytic Antibody-Based Cancer Therapy and was granted on 26 March 2019. The group received numerous grants from the government departments and agencies worth approximately thirty-five thousand dollars. The amount received is to be applied to PAT-DX1 devising and companyâs business development initiatives.
Also, the company recently presented at American Association for Cancer Research (AACR) in Georgia.
On the stock price performance front, PAB has been in a down trend. In the past year, the share has delivered a negative 38.46% returns. In the recent past it has delivered a return of -31.43%, -4.00%, in the past six months, three months respectively. However, in the last month period it delivered a yield of 14.29%. The stock of the company last traded at A$0.024 as on 18 April 2019. The stock has demonstrated negative YTD return of 14.29%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.